Related Experiment Videos
Non-acne dermatologic indications for systemic isotretinoin
1School of Medicine of Cumhuriyet University, Sivas, Turkey. makyol@cumhuriyet.edu.tr
American Journal of Clinical Dermatology
|June 10, 2005
Summary
Systemic isotretinoin, known for treating acne vulgaris, shows promise for various skin conditions due to its anti-inflammatory and anti-tumor effects. Further clinical trials are needed to confirm its efficacy beyond acne treatment.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Systemic isotretinoin is a well-established treatment for severe acne vulgaris.
- Its therapeutic potential extends beyond acne to numerous other dermatologic diseases.
Purpose of the Study:
- To explore the efficacy of systemic isotretinoin in various dermatologic conditions beyond acne vulgaris.
- To highlight the immunomodulatory, anti-inflammatory, and antitumor properties of isotretinoin.
Main Methods:
- Review of existing literature on systemic isotretinoin's use in diverse dermatologic conditions.
- Analysis of reported responses in diseases like psoriasis, skin cancers, and lupus erythematosus.
Main Results:
- Isotretinoin demonstrates efficacy in treating psoriasis, pityriasis rubra pilaris, condylomata acuminata, skin cancers, rosacea, hidradenitis suppurativa, granuloma annulare, lupus erythematosus, and lichen planus.
- It exhibits immunomodulatory, anti-inflammatory, and antitumor activities.
- Combination therapy with interferon-alpha-2a may enhance skin cancer prevention and treatment.
Conclusions:
- Systemic isotretinoin can be considered an alternative treatment for dermatologic diseases unresponsive to conventional therapies.
- Randomized clinical trials are necessary to definitively establish its role in conditions other than acne vulgaris.